Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic rationale for the rivastigmine patch.

Author: Appel-DingemanseSilke, CummingsJeffrey, LefèvreGilbert, SmallGary

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rivastigmine is a cholinesterase inhibitor approved for the symptomatic treatment of dementia associated with Alzheimer disease (AD) and Parkinson disease (PD). A recently developed rivastigmine transdermal patch may have the potential to reduce side effects, such as nausea and vomiting, while permitting similar exposure to the highest doses of capsules.
Paper Details　
Original Abstract of the Article :
The dual cholinesterase inhibitor rivastigmine is approved in capsule form in many countries for the symptomatic treatment of dementia associated with Alzheimer disease (AD) and Parkinson disease (PD). All orally administered cholinesterase inhibitors are associated with central cholinergic gastroin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/01.wnl.0000281846.40390.50

データ提供：米国国立医学図書館（NLM）

Rivastigmine Patch: A New Approach for Alzheimer's and Parkinson's Disease Treatment

The search for effective treatments for Alzheimer's and Parkinson's disease is a continuous pursuit, with researchers striving to find ways to improve patient outcomes. This study explores the potential benefits of a transdermal rivastigmine patch as an alternative delivery method for this cholinesterase inhibitor.

Rivastigmine, a dual cholinesterase inhibitor, is commonly used to treat dementia associated with Alzheimer's and Parkinson's disease. While oral administration is effective, it can lead to gastrointestinal side effects, particularly during the titration phase. The researchers investigated the pharmacokinetic properties of a rivastigmine patch, comparing it to the oral capsule form. Their findings revealed that the patch prolongs the time to peak concentration (tmax), lowers the peak concentration (Cmax), and reduces fluctuations in plasma concentration compared to oral administration.

A More Tolerable Approach: Improving Treatment Compliance

The study's findings suggest that the rivastigmine patch may offer a more tolerable and convenient treatment option for patients with Alzheimer's and Parkinson's disease. By reducing gastrointestinal side effects, the patch may improve patient compliance and potentially lead to better outcomes.

Managing Dementia: Finding the Right Path

For patients with Alzheimer's and Parkinson's disease, finding the right treatment strategy is essential. The rivastigmine patch offers a promising alternative to oral administration, potentially reducing side effects and improving treatment compliance.

Dr. Camel's Conclusion

The development of a rivastigmine patch represents a significant advancement in the treatment of Alzheimer's and Parkinson's disease. Just as a camel navigates the desert with its unique adaptations, the rivastigmine patch offers a more adaptable and potentially more effective way to manage these challenging conditions.

Date :
  1. Date Completed 2007-08-16
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

17646618

DOI: Digital Object Identifier

10.1212/01.wnl.0000281846.40390.50

Related Literature

Article Analysis
・Side Effects of rivastigmine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.